DexCom Inc (DXCM)

NASDAQ
Currency in USD
79.94
-1.08(-1.33%)
Real-time Data·
DXCM Scorecard
Full Analysis
Management has been aggressively buying back shares
DXCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
79.7082.06
52 wk Range
57.52117.27
Key Statistics
Edit
Prev. Close
81.01
Open
81.6
Day's Range
79.7-82.06
52 wk Range
57.52-117.27
Volume
1.53M
Average Vol. (3m)
4M
1-Year Change
-30.55%
Book Value / Share
5.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXCM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
98.59
Upside
+23.32%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

DexCom Inc News & Analysis

Show more

DexCom Inc Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc SWOT Analysis


Growth Trajectory
Discover DexCom's expansion strategies, including Type 2 diabetes market penetration and international growth, with analyst price targets ranging from $93 to $103.
Innovation Pipeline
Learn about DexCom's game-changing G7 15-Day CGM system and strategic partnerships, positioning the company for future growth in diabetes management.
Financial Resilience
Delve into DexCom's robust financial performance, including a 14% year-over-year sales increase and projected revenue of $4.6 billion for 2025.
CGM Market Leade
Explore DexCom's dominance in Continuous Glucose Monitoring, with $4.15 billion in revenue and a 24% return on equity, showcasing its strong market position.
Read full SWOT analysis

DexCom Inc Earnings Call Summary for Q1/2025

  • DexCom Q1 2025 revenue beat expectations at $1.04B, up 14% YoY, driven by strong U.S. sales; EPS slightly missed at $0.32
  • Company announced $750M share repurchase program and launched new products including Stello CGM and 15-day Com G7 system
  • Full-year revenue guidance set at $4.6B, representing 14% growth; gross margin guidance adjusted to approximately 62%
  • Stock rose 3.2% in after-hours trading to $72.51; analysts maintain positive outlook with price targets ranging from $80 to $115
  • CEO highlighted value of products in cost savings; CFO noted opportunities for expanding Type 2 diabetes coverage in 2025
Last Updated: 05/01/2025, 05:46 PM
Read Full Transcript

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
59.1x−4.6x−0.5x
PEG Ratio
−4.44−0.160.00
Price / Book
13.9x3.6x2.6x
Price / LTM Sales
7.6x2.5x3.0x
Upside (Analyst Target)
23.9%101.4%51.9%
Fair Value Upside
Unlock−28.4%8.9%Unlock

Analyst Ratings

24 Buy
3 Hold
0 Sell
Ratings:
27 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 98.59
(+23.32% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
0.32 / 0.33
Revenue / Forecast
1.04B / 1.02B
EPS Revisions
Last 90 days

DXCM Income Statement

People Also Watch

322.65
APP
-6.31%
304.21
CEG
-0.72%
469.98
SNPS
-0.77%
52.40
ON
+0.26%
304.47
UNH
-0.89%

FAQ

What Is the DexCom (DXCM) Stock Price Today?

The DexCom stock price today is 79.94

What Stock Exchange Does DexCom Trade On?

DexCom is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for DexCom?

The stock symbol for DexCom is "DXCM."

What Is the DexCom Market Cap?

As of today, DexCom market cap is 31.41B.

What Is DexCom's Earnings Per Share (TTM)?

The DexCom EPS (TTM) is 1.36.

When Is the Next DexCom Earnings Date?

DexCom will release its next earnings report on Jul 24, 2025.

From a Technical Analysis Perspective, Is DXCM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has DexCom Stock Split?

DexCom has split 1 times.

How Many Employees Does DexCom Have?

DexCom has 10250 employees.

What is the current trading status of DexCom (DXCM)?

As of Jun 20, 2025, DexCom (DXCM) is trading at a price of 79.94, with a previous close of 81.01. The stock has fluctuated within a day range of 79.70 to 82.06, while its 52-week range spans from 57.52 to 117.27.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.